STOCK TITAN
  1. Home
  2. Sec-filings
  3. CBIO
  4. [Form 4] CRESCENT BIOPHARMA, INC. Insider Trading Activity

Crescent BioPharma (CBIO) COO tax-related sale of 20,549 shares

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

CRESCENT BIOPHARMA, INC. President and COO Jonathan McNeill reported an open-market sale of 20,549 Ordinary Shares at a weighted average price of $17.99 per share. According to the filing, the shares were automatically sold to cover tax withholding obligations from vesting restricted stock units under a pre-arranged Rule 10b5-1 instruction. After these tax-related sales, McNeill directly holds 139,158 Ordinary Shares.

Positive

  • None.

Negative

  • None.

Insights

Routine, pre-planned tax-related sale with substantial holdings retained.

President and COO Jonathan McNeill sold 20,549 Ordinary Shares at a weighted average price of $17.99 per share. The footnotes explain these shares were automatically sold to satisfy tax withholding obligations tied to restricted stock unit vesting.

The sale was executed under a pre-arranged Rule 10b5-1 instruction adopted on February 25, 2026, indicating a planned, mechanical transaction rather than discretionary market timing. Following the sale, McNeill still directly owns 139,158 Ordinary Shares, suggesting this represents a small portion of his overall position.

Insider McNeill Jonathan
Role President and COO
Sold 20,549 shs ($370K)
Type Security Shares Price Value
Sale Ordinary Shares 20,549 $17.99 $370K
Holdings After Transaction: Ordinary Shares — 139,158 shares (Direct, null)
Footnotes (1)
  1. Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025 and March 17, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.88 to $18.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
Shares sold 20,549 shares Open-market sale on June 22, 2026
Weighted average sale price $17.99 per share Ordinary Shares sold to cover taxes
Price range of sales $16.88 to $18.86 Multiple transactions included in reported sale
Shares held after transaction 139,158 shares Direct ownership by President and COO after sale
RSU grant dates December 15, 2025 and March 17, 2025 Restricted stock units whose vesting triggered tax sale
Rule 10b5-1 adoption date February 25, 2026 Pre-arranged trading instruction covering these sales
Rule 10b5-1 regulatory
"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
restricted stock units financial
"in connection with the settlement of restricted stock units granted to the Reporting Person"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
tax withholding obligations financial
"shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement"
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
McNeill Jonathan
(Last)(First)(Middle)
C/O CRESCENT BIOPHARMA, INC.
300 FIFTH AVENUE
(Street)
WALTHAM MASSACHUSETTS 02451
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
CRESCENT BIOPHARMA, INC. [ CBIO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
President and COO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Ordinary Shares06/22/2026S20,549(1)D$17.99(2)139,158D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025 and March 17, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.88 to $18.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
Remarks:
/s/ Barbara Bispham, as attorney-in-fact for Jonathan McNeill06/23/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Crescent BioPharma (CBIO) report for Jonathan McNeill?

Crescent BioPharma reported that President and COO Jonathan McNeill sold 20,549 Ordinary Shares. The sale occurred at a weighted average price of $17.99 per share and was disclosed as an open-market transaction on the Form 4 insider trading report.

Why did Crescent BioPharma’s COO sell 20,549 CBIO shares?

The shares were automatically sold to cover tax withholding obligations from vesting restricted stock units. Footnotes state the sales were made solely to satisfy taxes related to RSU settlements rather than discretionary portfolio rebalancing or directional trading in Crescent BioPharma stock.

Was the Crescent BioPharma (CBIO) insider sale made under a Rule 10b5-1 plan?

Yes. The filing notes the sales were effected under a Rule 10b5-1 instruction adopted on February 25, 2026. Such pre-arranged plans schedule trades in advance, making the timing less indicative of the insider’s current view on Crescent BioPharma shares.

What price range did Crescent BioPharma’s COO receive for the 20,549 shares sold?

The weighted average sale price was $17.99 per share. Footnotes explain that individual trades occurred at prices ranging from $16.88 to $18.86, and detailed trade-level pricing information is available upon request from Crescent BioPharma or the reporting person.

How many Crescent BioPharma (CBIO) shares does the COO hold after this Form 4 sale?

After completing the tax-related sale, President and COO Jonathan McNeill directly holds 139,158 Ordinary Shares. This remaining stake shows he continues to maintain a significant equity interest in Crescent BioPharma following the automatic sale for tax withholding purposes.